Drug Profile
PF 4895162
Alternative Names: PF-04895162Latest Information Update: 24 Apr 2016
Price :
$50
*
At a glance
- Originator Pfizer
- Class Antiepileptic drugs
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Epilepsy
Most Recent Events
- 26 Mar 2013 Pfizer completes a phase I trial in Healthy volunteers in USA (NCT01691274)
- 31 Oct 2012 Phase-I clinical trials in Epilepsy in USA (PO)
- 19 Sep 2012 Preclinical trials in Epilepsy in USA (PO)